Shopping Cart 0
Cart Subtotal
AED 0

Almirall SA (ALM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 0

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 0

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 0

Details

Summary

Almirall SA (Almirall) is a specialty pharmaceutical company which researches, develops, manufactures and commercializes proprietary medicines and licensed products. The company's key area of focus is dermatology covering psoriasis, eczema, acne and other skin infections. It also develops products in the autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. Some of its major products include Actikerall, Balneum; Solaraze; Decoderm and Sativex among others. The company also works together with small and medium sized companies for the development of drugs and their marketing. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.

Almirall SA (ALM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Almirall SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Almirall SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Almirall SA, Medical Devices Deals, 2012 to YTD 2018 12

Almirall SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Almirall SA, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Almirall Acquires Dermatology Portfolio from Allergan 15

Almirall Acquires Rights to Veltin and Altabax from Stiefel 16

Aqua Pharma Acquires US Rights To Verdeso Foam From Stiefel 17

Partnerships 18

Evotec and Almirall Enter into Research Agreement 18

Almirall Enters into Research Agreement with Mercachem 19

Nuevolution Enters into Co-Development Agreement with Almirall 20

Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 21

Almirall Enters Into Commercialization Agreement With Quintiles 22

Bayer HealthCare And Almirall Enter Into Co-Promotion Agreement For Rivaroxaban In Spain 23

Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 24

Licensing Agreements 25

Almirall Enters into Licensing Agreement with AstraZeneca 25

Almirall Signs Licensing Agreement with Athenex for KX2-391 26

Luqa Pharma Enters into Licensing Agreement with Polichem 27

Almirall Enters into Licensing Agreement with Patagonia Pharma 28

Almirall Enters into Licensing Agreement with Bicosome 29

Allergan Enters into Licensing Agreement with Almirall for Constella 30

Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 31

Almirall Enters into Licensing Agreement with Sun Pharma for Tildrakizumab 32

Laboratorios Rubio Enters Into Licensing Agreement With Polichem 33

Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 34

Almirall Enters Into Licensing Agreement With Invida For Aclidinium 35

Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 37

Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 38

Almirall Enters Into Licensing Agreement With Daewoong Pharma For Aclidinium 39

Equity Offering 40

Suneva Medical Raises USD15 Million in Series C Equity Investment 40

Debt Offering 41

Almirall Raises USD447.4 Million in Private Placement of 4.625% Notes Due 2021 41

Asset Transactions 42

Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 42

Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 43

Acquisition 45

Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 45

Almirall Acquires Poli 46

Actavis May Acquire Almirall 47

Almirall Completes Acquisition Of Aqua Pharma From RoundTable Healthcare Partners For USD 403 Million 48

Almirall Acquires Stake In AB-Biotics, Biotechnology Company, For USD 1.3 Million 50

Almirall SA-Key Competitors 51

Almirall SA-Key Employees 52

Almirall SA-Locations And Subsidiaries 53

Head Office 53

Other Locations & Subsidiaries 53

Recent Developments 55

Strategy And Business Planning 55

Aug 06, 2018: Allergan divests five dermatology medicines to Almirall for USD 550m 55

Sep 13, 2017: Almirall Renews its Corporate Identity, Aligned with its Focus on Skin Health 56

Financial Announcements 57

May 14, 2018: Almirall Announces Financial Results Q1 2018 57

Feb 23, 2018: Almirall's Full-Year 2017 Results 59

Nov 06, 2017: Almirall's Q3 results 2017 61

Jul 24, 2017: Almirall's H1 Results 2017: Reiterating Recent Guidance 63

May 08, 2017: Almirall's Q1 results 2017, driven by Dermatology in Europe 64

Feb 27, 2017: Almirall Full-Year 2016 results: Strong Dermatology results and promising pipeline 66

Corporate Communications 68

Aug 22, 2017: Almirall announces Ron Menezes as new President & General Manager at Aqua Pharmaceuticals 68

Appendix 69

Methodology 69

About GlobalData 69

Contact Us 69

Disclaimer 69


List Of Figure

List of Figures

Almirall SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Almirall SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Almirall SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Almirall SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Almirall SA, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Almirall SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Almirall SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Almirall SA, Deals By Therapy Area, 2012 to YTD 2018 10

Almirall SA, Medical Devices Deals, 2012 to YTD 2018 12

Almirall SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Almirall Acquires Dermatology Portfolio from Allergan 15

Almirall Acquires Rights to Veltin and Altabax from Stiefel 16

Aqua Pharma Acquires US Rights To Verdeso Foam From Stiefel 17

Evotec and Almirall Enter into Research Agreement 18

Almirall Enters into Research Agreement with Mercachem 19

Nuevolution Enters into Co-Development Agreement with Almirall 20

Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 21

Almirall Enters Into Commercialization Agreement With Quintiles 22

Bayer HealthCare And Almirall Enter Into Co-Promotion Agreement For Rivaroxaban In Spain 23

Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 24

Almirall Enters into Licensing Agreement with AstraZeneca 25

Almirall Signs Licensing Agreement with Athenex for KX2-391 26

Luqa Pharma Enters into Licensing Agreement with Polichem 27

Almirall Enters into Licensing Agreement with Patagonia Pharma 28

Almirall Enters into Licensing Agreement with Bicosome 29

Allergan Enters into Licensing Agreement with Almirall for Constella 30

Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 31

Almirall Enters into Licensing Agreement with Sun Pharma for Tildrakizumab 32

Laboratorios Rubio Enters Into Licensing Agreement With Polichem 33

Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 34

Almirall Enters Into Licensing Agreement With Invida For Aclidinium 35

Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 37

Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 38

Almirall Enters Into Licensing Agreement With Daewoong Pharma For Aclidinium 39

Suneva Medical Raises USD15 Million in Series C Equity Investment 40

Almirall Raises USD447.4 Million in Private Placement of 4.625% Notes Due 2021 41

Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 42

Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 43

Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 45

Almirall Acquires Poli 46

Actavis May Acquire Almirall 47

Almirall Completes Acquisition Of Aqua Pharma From RoundTable Healthcare Partners For USD 403 Million 48

Almirall Acquires Stake In AB-Biotics, Biotechnology Company, For USD 1.3 Million 50

Almirall SA, Key Competitors 51

Almirall SA, Key Employees 52

Almirall SA, Subsidiaries 53

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Almirall SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Almirall SA (Almirall) is a specialty pharmaceutical company which researches, develops, manufactures and commercializes proprietary medicines and licensed products. The company's key area of focus is dermatology covering psoriasis, eczema, acne and other skin infections. It also develops products in the autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. Some of its major products include Actikerall, Balneum; Solaraze; Decoderm and Sativex among others. The company also works together with small and medium sized companies for the development of drugs and their marketing. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.

Almirall SA (ALM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Almirall SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Almirall SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Almirall SA, Medical Devices Deals, 2012 to YTD 2018 12

Almirall SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Almirall SA, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Almirall Acquires Dermatology Portfolio from Allergan 15

Almirall Acquires Rights to Veltin and Altabax from Stiefel 16

Aqua Pharma Acquires US Rights To Verdeso Foam From Stiefel 17

Partnerships 18

Evotec and Almirall Enter into Research Agreement 18

Almirall Enters into Research Agreement with Mercachem 19

Nuevolution Enters into Co-Development Agreement with Almirall 20

Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 21

Almirall Enters Into Commercialization Agreement With Quintiles 22

Bayer HealthCare And Almirall Enter Into Co-Promotion Agreement For Rivaroxaban In Spain 23

Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 24

Licensing Agreements 25

Almirall Enters into Licensing Agreement with AstraZeneca 25

Almirall Signs Licensing Agreement with Athenex for KX2-391 26

Luqa Pharma Enters into Licensing Agreement with Polichem 27

Almirall Enters into Licensing Agreement with Patagonia Pharma 28

Almirall Enters into Licensing Agreement with Bicosome 29

Allergan Enters into Licensing Agreement with Almirall for Constella 30

Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 31

Almirall Enters into Licensing Agreement with Sun Pharma for Tildrakizumab 32

Laboratorios Rubio Enters Into Licensing Agreement With Polichem 33

Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 34

Almirall Enters Into Licensing Agreement With Invida For Aclidinium 35

Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 37

Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 38

Almirall Enters Into Licensing Agreement With Daewoong Pharma For Aclidinium 39

Equity Offering 40

Suneva Medical Raises USD15 Million in Series C Equity Investment 40

Debt Offering 41

Almirall Raises USD447.4 Million in Private Placement of 4.625% Notes Due 2021 41

Asset Transactions 42

Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 42

Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 43

Acquisition 45

Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 45

Almirall Acquires Poli 46

Actavis May Acquire Almirall 47

Almirall Completes Acquisition Of Aqua Pharma From RoundTable Healthcare Partners For USD 403 Million 48

Almirall Acquires Stake In AB-Biotics, Biotechnology Company, For USD 1.3 Million 50

Almirall SA-Key Competitors 51

Almirall SA-Key Employees 52

Almirall SA-Locations And Subsidiaries 53

Head Office 53

Other Locations & Subsidiaries 53

Recent Developments 55

Strategy And Business Planning 55

Aug 06, 2018: Allergan divests five dermatology medicines to Almirall for USD 550m 55

Sep 13, 2017: Almirall Renews its Corporate Identity, Aligned with its Focus on Skin Health 56

Financial Announcements 57

May 14, 2018: Almirall Announces Financial Results Q1 2018 57

Feb 23, 2018: Almirall's Full-Year 2017 Results 59

Nov 06, 2017: Almirall's Q3 results 2017 61

Jul 24, 2017: Almirall's H1 Results 2017: Reiterating Recent Guidance 63

May 08, 2017: Almirall's Q1 results 2017, driven by Dermatology in Europe 64

Feb 27, 2017: Almirall Full-Year 2016 results: Strong Dermatology results and promising pipeline 66

Corporate Communications 68

Aug 22, 2017: Almirall announces Ron Menezes as new President & General Manager at Aqua Pharmaceuticals 68

Appendix 69

Methodology 69

About GlobalData 69

Contact Us 69

Disclaimer 69


List Of Figure

List of Figures

Almirall SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Almirall SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Almirall SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Almirall SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Almirall SA, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Almirall SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Almirall SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Almirall SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Almirall SA, Deals By Therapy Area, 2012 to YTD 2018 10

Almirall SA, Medical Devices Deals, 2012 to YTD 2018 12

Almirall SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Almirall Acquires Dermatology Portfolio from Allergan 15

Almirall Acquires Rights to Veltin and Altabax from Stiefel 16

Aqua Pharma Acquires US Rights To Verdeso Foam From Stiefel 17

Evotec and Almirall Enter into Research Agreement 18

Almirall Enters into Research Agreement with Mercachem 19

Nuevolution Enters into Co-Development Agreement with Almirall 20

Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 21

Almirall Enters Into Commercialization Agreement With Quintiles 22

Bayer HealthCare And Almirall Enter Into Co-Promotion Agreement For Rivaroxaban In Spain 23

Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 24

Almirall Enters into Licensing Agreement with AstraZeneca 25

Almirall Signs Licensing Agreement with Athenex for KX2-391 26

Luqa Pharma Enters into Licensing Agreement with Polichem 27

Almirall Enters into Licensing Agreement with Patagonia Pharma 28

Almirall Enters into Licensing Agreement with Bicosome 29

Allergan Enters into Licensing Agreement with Almirall for Constella 30

Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 31

Almirall Enters into Licensing Agreement with Sun Pharma for Tildrakizumab 32

Laboratorios Rubio Enters Into Licensing Agreement With Polichem 33

Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 34

Almirall Enters Into Licensing Agreement With Invida For Aclidinium 35

Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 37

Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 38

Almirall Enters Into Licensing Agreement With Daewoong Pharma For Aclidinium 39

Suneva Medical Raises USD15 Million in Series C Equity Investment 40

Almirall Raises USD447.4 Million in Private Placement of 4.625% Notes Due 2021 41

Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 42

Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 43

Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 45

Almirall Acquires Poli 46

Actavis May Acquire Almirall 47

Almirall Completes Acquisition Of Aqua Pharma From RoundTable Healthcare Partners For USD 403 Million 48

Almirall Acquires Stake In AB-Biotics, Biotechnology Company, For USD 1.3 Million 50

Almirall SA, Key Competitors 51

Almirall SA, Key Employees 52

Almirall SA, Subsidiaries 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Almirall SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.